Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition

Sivrioglu E. Y., Topaloglu V. M., Sarandol A., Akkaya C., Eker S. S., Kirli S.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.31, sa.2, ss.548-550, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 31 Sayı: 2
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.pnpbp.2006.10.006
  • Dergi Adı: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.548-550
  • Anahtar Kelimeler: erectile dysfunction, premature ejaculation, reboxetine, sexual dysfunction, spontaneous ejaculation, INDUCED SEXUAL DYSFUNCTION, ANTIDEPRESSANTS, PHARMACOLOGY, DISORDERS, SEROTONIN
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

This is a case report of reboxetine induced erectile dysfunction, seminal emission and ejaculation during defecation and micturition. A 44 year old male who had been suffering from depression without any sexual dysfunction was put on venlafaxine XR treatment. Due to delayed ejaculation and occasional episodes of absence of ejaculation he was switched to reboxetine. At the second week of treatment he reported erectile dysfunction and premature ejaculation, and seminal emission and ejaculation during defecation and micturition occurred later at 8th week of treatment. After he was switched to sertraline 50 mg/day, his erectile dysfunction, premature and spontaneous ejaculation symptoms subsided in 2 weeks. Although reboxetine is reported to be free of sexual side effects, individual vulnerabilities to such unwanted effects should be considered, and sexual dysfunction should be assessed thoroughly during the treatment. (c) 2006 Elsevier Inc. All rights reserved.